Search results
Results from the WOW.Com Content Network
The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. Learn more » *Stock Advisor returns as of January 21, 2025. Adria Cimino has no position in any of the stocks ...
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. Will that trend continue in ...
The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. Learn more » *Stock Advisor returns as of February 3, 2025. Dan Victor has no position in any of the stocks ...
In the third quarter, the company's revenue of $2.77 billion increased by 12% year over year, a strong performance for a biotech giant. The company's best CF treatment yet, Trikafta, accounted for ...
CRISPR's shares are down by 27% year to date, and Moderna's are down by 41%. Regardless of their performances so far in 2024, both stocks are worth investing in this month. Read on to find out why. 1.
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an impressive resume already, but it's just getting started. It's currently in the ...
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond. ... plunged over 30% this year. Moderna is roughly 86% below its peak set in 2021 ...
Here are three no-brainer biotech stocks to buy with $200 right now. Biotech stocks usually appeal more to aggressive growth investors, while value investors typically prefer to look elsewhere.